PharmaShots | Incisive News in 3 Shots

Subscribe Now

Intellia

Intellia’s NTLA-2002 Receives the US FDA’s ODD for the Treatment of Hereditary Angioedema

Intellia’s NTLA-2002 Receives the US FDA’s ODD for the Treatment of Hereditary Angioedema

September 2, 2022

Intellia and Regeneron Present Updated Interim Data of NTLA-2001 in P-I Study for the Treatment of Transthyretin Amyloidosis at EASL 2022

Intellia and Regeneron Present Updated Interim Data of NTLA-2001 in P-I Study for the Treatment of Transthyretin Amyloidosis at EA...

June 27, 2022

Intellia Signs a License and Collaboration Agreement with ONK to Advance Allogeneic CRISPR-Edited NK Cell Therapies for Cancer

Intellia Signs a License and Collaboration Agreement with ONK to Advance Allogeneic CRISPR-Edited NK Cell Therapies for Cancer

February 16, 2022

Intellia Entered into a License Agreement with Kyverna to Develop KYV-201 for the Treatment of Autoimmune Diseases

Intellia Entered into a License Agreement with Kyverna to Develop KYV-201 for the Treatment of Autoimmune Diseases

January 6, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us